Bacterial membrane vesicles (BMVs) are known to be critical communication tools in several pathophysiological processes between bacteria and host cells. Given this situation, BMVs for transporting and delivering exogenous therapeutic cargoes have been inspiring as promising platforms for developing smart drug delivery systems (SDDSs). In the first section of this review paper, starting with an introduction to pharmaceutical technology and nanotechnology, we delve into the design and classification of SDDSs. We discuss the characteristics of BMVs including their size, shape, charge, effective production and purification techniques, and the different methods used for cargo loading and drug encapsulation. We also shed light on the drug release mechanism, the design of BMVs as smart carriers, and recent remarkable findings on the potential of BMVs for anticancer and antimicrobial therapy. Furthermore, this review covers the safety of BMVs and the challenges that need to be overcome for clinical use. Finally, we discuss the recent advancements and prospects for BMVs as SDDSs and highlight their potential in revolutionizing the fields of nanomedicine and drug delivery. In conclusion, this review paper aims to provide a comprehensive overview of the state-of-the-art field of BMVs as SDDSs, encompassing their design, composition, fabrication, purification, and characterization, as well as the various strategies used for targeted delivery. Considering this information, the aim of this review is to provide researchers in the field with a comprehensive understanding of the current state of BMVs as SDDSs, enabling them to identify critical gaps and formulate new hypotheses to accelerate the progress of the field.

During 2020, the world has experienced extreme vulnerability in the face of a disease outbreak. The coronavirus disease 2019 (COVID-19) pandemic discovered in China and rapidly spread across the globe, infecting millions, causing hundreds of thousands of deaths, and severe downturns in the economies of countries worldwide. Biosurfactants can play a significant role in the prevention, control and treatment of diseases caused by these pathogenic agents through various therapeutic, pharmaceutical, environmental and hygiene approaches. Biosurfactants have the potential to inhibit microbial species with virulent intrinsic characteristics capable of developing diseases with high morbidity and mortality, as well as interrupting their spread through environmental and hygiene interventions. This is possible due to their antimicrobial activity, ability to interact with cells forming micelles and to interact with the immune system, and compatibility with relevant processes such as nanoparticle synthesis. They, therefore, can be applied in developing innovative and more effective pharmaceutical, therapeutics, sustainable and friendly environmental management approaches, less toxic formulations, and more efficient cleaning agents. These approaches can be easily integrated into relevant product development pipelines and implemented as measures for combating and managing pandemics. This review examines the potential approaches of biosurfactants as useful molecules in fighting microbial pathogens both known and previously unknown, such as COVID-19.

Salt tolerant organisms are increasingly being used for the industrial production of high‐value biomolecules due to their better adaptability compared to mesophiles. Chromohalobacter canadensis is one of the early halophiles to show promising biotechnology potential, which has not been explored to date. Advanced high throughput technologies such as whole‐genome sequencing allow in‐depth insight into the potential of organisms while at the frontiers of systems biology. At the same time, genome‐scale metabolic models (GEMs) enable phenotype predictions through a mechanistic representation of metabolism. Here, we sequence and analyze the genome of C. canadensis 85B, and we use it to reconstruct a GEM. We then analyze the GEM using flux balance analysis and validate it against literature data on C. canadensis. We show that C. canadensis 85B is a metabolically versatile organism with many features for stress and osmotic adaptation. Pathways to produce ectoine and polyhydroxybutyrates were also predicted. The GEM reveals the ability to grow on several carbon sources in a minimal medium and reproduce osmoadaptation phenotypes. Overall, this study reveals insights from the genome of C. canadensis 85B, providing genomic data and a draft GEM that will serve as the first steps towards a better understanding of its metabolism, for novel applications in industrial biotechnology.

Eighty-seven bacteria isolates were screened for the presence of the levansucrase encoding gene and those possessing the gene were used in gene expression studies and the production of levan. Based on both screening methods, isolate P19-1 was determined as the producer bacterium with the highest amounts of levan. Whole genome sequencing was done to characterize the isolate and determine its genomic potential. Both its 16 S rRNA and genome were closest to Chromohalobacter salexigens. The levansucrase gene and genes suggesting a versatile carbohydrate and nitrogen metabolism were annotated. A secondary metabolism suggestive of a possible new role in promoting plant growth in hypersaline environments was revealed. The chemical structure analysis of the produced polymer was confirmed by comparison with commercial pure Erwinia herbicola levan. Also, C. salexigens levan showed high biocompatibility. Overall, this is a practical molecular approach that will help researchers to effectively screen microbes with levan production potential.

Genome-scale metabolic models (GEMs) are indispensable for studying and engineering cellular metabolism. Here, we present i CHO3K, a community-consensus, manually-curated reconstruction of the Chinese Hamster metabolic network. In addition to accounting for 11004 reactions associated with 3597 genes, i CHO3K includes 3489 protein structures and structural descriptors for >70% of its 7377 metabolites, enabling deeper exploration of the link between molecular structure and cellular metabolism. We used i CHO3K to contextualize transcriptomics and metabolomics data from a CHO cell line in which lactate secretion is abolished. We found the reduced glycolytic flux and enhanced TCA cycle flux were accompanied by an elevated NADH and PEP levels in these cells, consistent with experimental measurements. Leveraging i CHO3K’s structural annotations, we identified candidate binding interactions of NADH and PEP with glycolytic enzymes showing model-predicted differential flux, suggesting novel allosteric regulation associated with the observed decrease in glucose uptake and glycolysis. Overall, i CHO3K offers a valuable framework for systematic integration of omics data, improved flux predictions, and structure-guided insights, thus advancing CHO cell engineering and enhancing biomanufacturing efficiency.